Veterinary Analgesics (VETERINARY TECHNICIAN EDUCATION)

Summary: Veterinary Analgesics

The lecture introduces pharmacology for veterinary technician students, focusing on analgesia and opioids. Its central message is that pain control requires understanding how pain signals travel, choosing and monitoring medications carefully, and preventing pain where possible rather than trying to control it only after it becomes severe.

Veterinary Technicians and Medication Safety

• Veterinary technicians help identify normal and abnormal drug responses, monitor patients during treatment, assess responses, and alert the veterinarian to adverse effects.
• Technicians do not prescribe medications. If a patient has a concerning reaction, the veterinarian should be contacted promptly.
• Drug doses are estimates, not guarantees. Patients may respond differently even when they are the same species or breed. The lecturer warns against treating every patient alike or becoming complacent.
• A valid veterinarian–client–patient relationship (VCPR; called VPCR in the subtitles) is required before medication is prescribed or administered to a patient.
• The lecture reviews common medication terminology:
  • Generic name: The drug’s common name.
  • Trade name: The name given to a drug by a manufacturer.
  • Generic equivalent: A product marketed as a generic version of a drug.
  • Over-the-counter and prescription drugs: The lecture focuses on prescription, or “legend,” medications.
  • Controlled drugs: Medications subject to additional tracking and regulatory requirements, including opioids.
• A medication label should identify the clinic and veterinarian, client and patient, drug and strength, directions, expiration date, and quantity.
• Controlled-drug logs should document the drug and its strength, each use or dispensing, patient and client details, the staff member responsible, the amount used, and the updated balance. The lecture notes that controlled-drug records are inspected in Ontario.

Pain Pathway and Prevention

The lecturer describes four stages of the pain pathway:

1. Transduction: A painful stimulus activates pain receptors (nociceptors).
2. Transmission: Pain signals travel along peripheral nerves toward the spinal cord.
3. Modulation: Signals are influenced as they travel through the nervous system toward the brain.
4. Perception: The brain consciously registers the pain.

The lecture emphasizes blocking pain at multiple stages—often called a balanced or multimodal approach—rather than relying on a single intervention. Examples discussed include:

• Using a local anesthetic at the site before a painful procedure to limit transduction.
• Blocking peripheral nerves to reduce transmission of signals toward the spinal cord.
• Using analgesics that reduce or inhibit pain signaling as it proceeds toward the brain.
• Providing pain relief before or during a procedure, because preventing pain is generally easier than treating severe pain after it has developed.

The lecturer also cautions that an animal’s lack of movement under anesthesia does not necessarily mean pain signals have stopped. Pain prevention should therefore be part of the anesthetic plan.

Opioids: Action and General Effects

• Opiates are described as drugs derived from the poppy plant; opioids are synthetic or manufactured drugs that act on opioid receptors.
• The lecture focuses mainly on mu (μ) and kappa (κ) receptors, while also mentioning delta and sigma receptors.
  • Mu-receptor activity is associated with strong analgesia and can also cause respiratory depression.
  • Kappa-receptor activity is associated with analgesia and sedation.
• Opioids can act before and after a nerve-cell junction: they can reduce neurotransmitter release and inhibit activity in the receiving cell.
• The lecture defines:
  • Agonist: Binds to a receptor and activates it.
  • Antagonist: Binds but produces little or no activation, thereby blocking other drugs from acting at that receptor.
  • Partial agonist or mixed agonist–antagonist: Produces a more limited effect and may reduce the effect of a stronger agonist by occupying the same receptors.
• Possible opioid effects and adverse effects discussed include sedation, respiratory depression, vomiting, initial diarrhea, constipation with prolonged use, urinary retention, appetite changes, and dysphoria. Effects vary by drug, dose, route, and patient.
• Because opioids can suppress the cough reflex, the lecturer highlights the risk of regurgitated material entering the airway in sedated or anesthetized animals. Airway protection and careful monitoring are important.

Drugs Discussed

• Morphine: Presented as a reference point for comparing opioid potency. It is described as a mu agonist with some kappa activity. It may provide useful relief for dull or visceral pain, but the lecturer says it may be less suitable alone for sharp surgical pain. Potential effects include vomiting, salivation, sedation, respiratory depression, and dysphoria at higher doses. The lecture also discusses possible histamine release with intravenous use.
• Hydromorphone: Described as a potent, pure mu agonist with a longer duration of action than morphine in the lecture. A key safety point is to check the product concentration carefully, since the speaker says different concentrations may look similar. Possible effects include vomiting, salivation, respiratory depression, dysphoria, and temporary temperature elevation in cats.
• Fentanyl: Described as a potent, short-acting mu agonist, often given by continuous infusion in hospital. Transdermal patches may be used for longer-term postoperative relief, but their onset and absorption can vary.
  • Never cut a fentanyl patch, because its contents may leak and create dosing and exposure risks.
  • Owners need instructions for safe handling, monitoring, and what to do if a patch comes off. The speaker raises risks if a child or animal contacts or ingests a patch.
• Buprenorphine: Described as a partial mu agonist with a longer effect than butorphanol and comparatively fewer of the adverse effects associated with stronger opioids. The lecture notes that it can be given through oral mucous membranes, which may make administration easier in some patients. It may have a ceiling-like effect: increasing the dose may extend its duration rather than continually increase its effect.
• Butorphanol: Described as a kappa agonist with mixed or partial activity at mu receptors. The lecture presents it mainly as a sedative or cough suppressant, rather than a primary drug for sustained surgical pain relief. Because it can compete with stronger mu agonists, it may reduce their analgesic effect; the speaker cautions against combining it casually with drugs such as hydromorphone.
• Tramadol: Described as a centrally acting medication with several mechanisms, including effects on serotonin and norepinephrine reuptake. The lecture says its effectiveness in dogs is uncertain and that dogs may metabolize it poorly. It warns against combining it with selective serotonin reuptake inhibitors (SSRIs) because of the risk of serotonin syndrome.
• Meperidine (Demerol): Presented as a less commonly used opioid. The lecturer notes its short action, comparatively weaker analgesic effect, potential for cardiac depression, and addiction concerns.
• Naloxone (Narcan): Presented as an opioid antagonist used to reverse opioid effects, including respiratory depression. Since it also reverses analgesia, the patient may need another pain-control plan after its use.
• Apomorphine: Mentioned as a morphine derivative used to induce vomiting, particularly in dogs. The lecture says it works through dopamine receptors involved in the vomiting pathway.

Main Lessons

• Assess each patient individually; neither drug response nor dose can be assumed to be identical across patients.
• Monitor for both expected and adverse drug effects, and involve the veterinarian when a reaction is concerning.
• Use a planned, preventive approach to pain management and consider interventions at multiple stages of the pain pathway.
• Understand opioid receptor actions and potential interactions before combining medications.
• Treat controlled drugs—and fentanyl patches in particular—with careful tracking, storage, handling, and client education.

Speakers and Sources Featured

• Speaker: One veterinary technician educator/lecturer; no personal name is given in the subtitles.
• Sources or references mentioned: An unnamed course textbook; a physiology/tutorial image; Purdue University’s controlled-substance record as an example; and human medicine as a comparison for veterinary practice.
• Regulatory bodies mentioned: The Ontario veterinary regulator (referred to in the subtitles as the Ontario College of Veterinarians/College of Veterinary Surgeons) and the Government of Canada.